Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

445 ARTÍCULOS , VIENDO DEL 226 AL 240

Nano Carrier Drug Delivery Systems for the Treatment of Neuropsychiatric Disorders: Advantages and Limitations

Zorkina Y, Abramova O, Ushakova V, Morozova A, Zubkov E, Valikhov M, Melnikov P, Majouga A, Chekhonin V.

Molecules. 2020 Nov 13;25(22):5294. doi: 10.3390/molecules25225294.

Transthyretin Stabilization: An Emerging Strategy for the Treatment of Alzheimer's Disease?

Saponaro F, Kim JH, Chiellini G.

Int J Mol Sci. 2020 Nov 17;21(22):8672. doi: 10.3390/ijms21228672.

Therapeutic Strategies to Target Calcium Dysregulation in Alzheimer's Disease

Calvo-Rodriguez M, Kharitonova EK, Bacskai BJ.

Cells. 2020 Nov 20;9(11):2513. doi: 10.3390/cells9112513.

Non-steroidal Anti-inflammatory Drugs as Candidates for the Prevention or Treatment of Alzheimer's Disease: Do they Still Have a Role?

Villarejo-Galende A, González-Sánchez M, Blanco-Palmero VA, Llamas-Velasco S, Benito-León J.

Curr Alzheimer Res. 2020;17(11):1013-1022. doi: 10.2174/1567205017666201127163018.

Apolipoprotein J in Alzheimer's Disease: Shedding Light on Its Role with Cell Signaling Pathway Perspective and Possible Therapeutic Approaches

Moezzi SM, Mozafari N, Fazel-Hoseini SM, Nadimi-Parashkoohi S, Abbasi H, Ashrafi H, Azadi A.

ACS Chem Neurosci. 2020 Dec 16;11(24):4060-4072. doi: 10.1021/acschemneuro.0c00637. Epub 2020 Nov 29.

Souvenaid for Alzheimer's disease

Burckhardt M, Watzke S, Wienke A, Langer G, Fink A.

Cochrane Database Syst Rev. 2020 Dec 15;12(12):CD011679. doi: 10.1002/14651858.CD011679.pub2.

Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials

Tian Hui Kwan A, Arfaie S, Therriault J, Rosa-Neto P, Gauthier S.

Dement Geriatr Cogn Disord. 2020;49(4):334-348. doi: 10.1159/000511506. Epub 2020 Dec 15.

Therapeutic Targeting Strategies for Early- to Late-Staged Alzheimer's Disease

Kang YJ, Diep YN, Tran M, Cho H.

Int J Mol Sci. 2020 Dec 16;21(24):9591. doi: 10.3390/ijms21249591.

c-Jun N-Terminal Kinase Inhibitors as Potential Leads for New Therapeutics for Alzheimer's Diseases

Hepp Rehfeldt SC, Majolo F, Goettert MI, Laufer S.

Int J Mol Sci. 2020 Dec 18;21(24):9677. doi: 10.3390/ijms21249677.

Nutraceutical Approaches of Autophagy and Neuroinflammation in Alzheimer's Disease: A Systematic Review

Gruendler R, Hippe B, Sendula Jengic V, Peterlin B, Haslberger AG.

Molecules. 2020 Dec 18;25(24):6018. doi: 10.3390/molecules25246018.

Is There Justification to Treat Neurodegenerative Disorders by Repurposing Drugs? The Case of Alzheimer's Disease, Lithium, and Autophagy

Damri O, Shemesh N, Agam G.

Int J Mol Sci. 2020 Dec 27;22(1):189. doi: 10.3390/ijms22010189.

Alzheimer's Disease: The Unwanted Companion of Elderly

Chawla PA, Parikh V.

CNS Neurol Disord Drug Targets. 2020;19(9):646-647. doi: 10.2174/187152731909201119090829.

Advances in Drug Therapy for Alzheimer's Disease

Zhu CC, Fu SY, Chen YX, Li L, Mao RL, Wang JZ, Liu R, Liu Y, Wang XC.

Curr Med Sci. 2020 Dec;40(6):999-1008. doi: 10.1007/s11596-020-2281-2. Epub 2021 Jan 11.

Tau in Alzheimer's Disease: Pathological Alterations and an Attractive Therapeutic Target

Gu JL, Liu F.

Curr Med Sci. 2020 Dec;40(6):1009-1021. doi: 10.1007/s11596-020-2282-1. Epub 2021 Jan 11.

Inflammation in Alzheimer's Disease

Fakhoury M.

Curr Alzheimer Res. 2020;17(11):959-961. doi: 10.2174/156720501711210101110513.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias